United States · Bill · HR
H.R. 6038 (102nd)
To amend title 35, United States Code, to permit separate patent extensions for each product under a patent which is subject to full regulatory review and approval.
Introduced
25 September 1992
Last action
—
Status
Referred to the Subcommittee on Intellectual Property and Judicial Administration.
Sponsors
—
Subjects
Discovery layer
Source updated
16 January 2025
Summary
Amends Federal patent law to permit separate patent extensions for certain drug products: (1) under a patent which is subject to full regulatory review and approval; and (2) which were developed at a qualified nonprofit institution of higher education.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
2 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN
Introduced in House
summary · EN · 25 September 1992
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/102nd-congress/house-bill/6038
- Open data entity: https://api.congress.gov/v3/bill/102/hr/6038